Thermo Fisher Scientific, the world leader in serving science and a leading provider of drugs of abuse testing solutions, announced the official launch of the new Thermo Scientific DRI Hydrocodone/Hydromorphone Assay. The new assay is a homogeneous enzyme immunoassay that specifically detects hydrocodone and major metabolites in human urine at a 300 ng/mL cut-off.

The assay utilises liquid ready-to-use reagents, calibrators and controls, and can be run in qualitative and semi-quantitative modes. The assay has =100 per cent cross-reactivity to the major metabolites hydromorphone and hydromorphone glucuronide. DRI Hydrocodone / Hydromorphone Assay demonstrated good correlation with LC-MS/MS and has excellent assay precision. It is a sensitive, specific and easy-to-use screening tool for hydrocodone and major metabolites in urine samples. This assay is “For Criminal Justice and Forensic Use Only.”

Hydrocodone, a semi-synthetic opioid, is an antitussive (cough suppressant) and narcotic analgesic agent for the treatment of moderate to severe pain. Hydrocodone is the most frequently prescribed opiate in the United States. There are several hundred brand name and generic combinations of hydrocodone products marketed. The most frequently prescribed combination is hydrocodone and acetaminophen (Vicodin, Lortab).

“Vicodin” is a registered trademark of Abbvie Inc. Corporation. “Lortab” is a registered trademark of UCB Pharma Inc. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries.